Alkermes advances schizophrenia prodrugs in shift from drug delivery
This article was originally published in Scrip
Executive Summary
In its quest to become known as a drug developer as well as a drug delivery partner, Alkermes will report various data points for its central nervous system (CNS) pipeline in 2013, starting with Phase II plans for ALKS 3831 and a new patent for aripiprazole lauroxil (formerly ALKS 9070), which both treat schizophrenia.